Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Oliver C, Neels"'
Autor:
Francisco Alves, Inês F. Antunes, Emiliano Cazzola, Frederik Cleeren, Bart Cornelissen, Antonia Denkova, Jonathan Engle, Alain Faivre-Chauvet, Nic Gillings, Jeroen J. M. A. Hendrikx, Amir R. Jalilian, Nicholas P. van der Meulen, Renata Mikolajczak, Oliver C. Neels, Maroor R. A. Pillai, Raymond Reilly, Sietske Rubow, Yann Seimbille, Sarah Spreckelmeyer, Wiktor Szymanski, Carlotta Taddei
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 6, Iss 1, Pp 1-16 (2021)
Abstract Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results This commentary of highlights has resul
Externí odkaz:
https://doaj.org/article/1e1d1224cf1a42b3b079fc553d8870f9
Autor:
Sadahiro Naka, Tadashi Watabe, Kenta Kurimoto, Motohide Uemura, Fumihiko Soeda, Oliver C. Neels, Klaus Kopka, Mitsuaki Tatsumi, Hiroki Kato, Norio Nonomura, Eku Shimosegawa, Jens Cardinale, Frederik L. Giesel, Jun Hatazawa
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 5, Iss 1, Pp 1-17 (2020)
Abstract Background [18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of
Externí odkaz:
https://doaj.org/article/79539a886eca4b86840d8eb0fb31065e
Autor:
Christin Glowa, Peter Peschke, Stephan Brons, Oliver C. Neels, Klaus Kopka, Jürgen Debus, Christian P. Karger
Publikováno v:
Radiation Oncology, Vol 12, Iss 1, Pp 1-11 (2017)
Abstract Background To summarize the research activities of the “clinical research group heavy ion therapy”, funded by the German Research Foundation (DFG, KFO 214), on the impact of intrinsic tumor characteristics (grading, hypoxia) on local tum
Externí odkaz:
https://doaj.org/article/43c6970862d844848e06c1601e4a6f4d
Publikováno v:
Radiopraxis 14(2021), E83-E98
Der Nuklearmediziner 44(2021)02, 135-1521
Der Nuklearmediziner 44(2021)02, 135-1521
Im vorliegenden CME-Beitrag sollen die Grundlagen des Theranostik-Prinzips beginnend bei den Eigenschaften der Radionuklide sowie deren Verfügbarkeit erläutert werden. Anhand von medizinischen und chemischen Beispielen aus den prominentesten Anwend
Autor:
Jun Hatazawa, Hiroki Kato, Tadashi Watabe, Frederik L. Giesel, Mitsuaki Tatsumi, Jens Cardinale, Norio Nonomura, Fumihiko Soeda, Kenta Kurimoto, Motohide Uemura, Sadahiro Naka, Klaus Kopka, Oliver C. Neels, Eku Shimosegawa
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 5, Iss 1, Pp 1-17 (2020)
Background [18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemic
Publikováno v:
Reference Module in Biomedical Sciences
Clemens Decristoforo: Elsevier Reference Collection in Biomedical Sciences, Oxford, UK: Elsevier, 2021, 9780128012383
Clemens Decristoforo: Elsevier Reference Collection in Biomedical Sciences, Oxford, UK: Elsevier, 2021, 9780128012383
Chapter "Ions and small molecules as radiopharmaceuticals" in the Encyclopedia of Nuclear Medicine and Molecular Imaging, Volume 1: Basic principles and instrumentation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf9faf6cf07e67b9b34184c440a27843
https://doi.org/10.1016/b978-0-12-822960-6.00008-9
https://doi.org/10.1016/b978-0-12-822960-6.00008-9
Publikováno v:
Nuklearmedizin. 58:77-85
ZusammenfassungZiel des Aufsatzes ist es, wesentliche gesetzliche und regulatorische Aspekte zu beleuchten, die bei multizentrischen klinischen Prüfungen mit kurzlebigen PSMA-PET-Radiopharmaka im Hinblick auf die Etablierung einer dezentralen Herste
Autor:
Tadashi Watabe, Oliver C. Neels, Frederik L. Giesel, Mitsuaki Tatsumi, Jun Hatazawa, Genki Horitsugi, Eku Shimosegawa, Yuwei Liu, Klaus Kopka, Fumihiko Soeda, Sadahiro Naka
Publikováno v:
Journal of Nuclear Medicine. 60:1594-1599
PET radioligands with low molar activity (MA) may underestimate the quantity of the target of interest because of competitive binding of the target with unlabeled ligand. The aim of this study was to evaluate the change in the whole-body distribution
Autor:
Jens Cardinale, René Martin, Yvonne Remde, Martin Schäfer, Antje Hienzsch, Sandra Hübner, Anna-Maria Zerges, Heike Marx, Ronny Hesse, Klaus Weber, Rene Smits, Alexander Hoepping, Marco Müller, Oliver C. Neels, Klaus Kopka
Publikováno v:
Pharmaceuticals, Vol 10, Iss 4, p 77 (2017)
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer. In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [18F]PSMA-1
Externí odkaz:
https://doaj.org/article/012a9376d837485d86628cf7492476ce
Autor:
Sergio Todde, Martin Béhé, Thomas L. Mindt, Marianne Patt, Clemens Decristoforo, Petra Kolenc Peitl, Nic Gillings, Meltem Ocak, Jacek Koziorowski, Peter Laverman, James R. Ballinger, Oliver C. Neels, Valentina Ferrari, Olaug Hjelstuen, Philip H. Elsinga
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 6, Iss 1, Pp 1-22 (2021)
EJNMMI Radiopharmacy and Chemistry 6(2021), 8
EJNMMI radiopharmacy and chemistry, 6, 1
EJNMMI Radiopharmacy and Chemistry, 6(1):8. Springer
EJNMMI Radiopharmacy and Chemistry
EJNMMI radiopharmacy and chemistry, 6
EJNMMI Radiopharmacy and Chemistry 6(2021), 8
EJNMMI radiopharmacy and chemistry, 6, 1
EJNMMI Radiopharmacy and Chemistry, 6(1):8. Springer
EJNMMI Radiopharmacy and Chemistry
EJNMMI radiopharmacy and chemistry, 6
Contains fulltext : 232903.pdf (Publisher’s version ) (Open Access) This guideline on current good radiopharmacy practice (cGRPP) for small-scale preparation of radiopharmaceuticals represents the view of the Radiopharmacy Committee of the European